41 A potential for combining the rapamycin derivative RAD001 (everolimus) with the EGF/ErbB2/VEGF receptor tyrosine kinase inhibitor AEE788 in human cancer

Autor:	Heidi Lane, N. Hynes, C. Stephan, S. Ruetz, A. Boulay, J. Baselga, S. Gerboth, S. Zumstein-Mecker
Rok vydání:	2004
Předmět:	Cancer Research Everolimus biology medicine.drug_class Chemistry Tropomyosin receptor kinase C Tyrosine-kinase inhibitor Receptor tyrosine kinase Oncology ROR1 medicine biology.protein Cancer research Tyrosine kinase Platelet-derived growth factor receptor Proto-oncogene tyrosine-protein kinase Src medicine.drug
Zdroj:	European Journal of Cancer Supplements. 2:16
ISSN:	1359-6349
DOI:	10.1016/s1359-6349(04)80049-1
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::da3b0997cb69b6da5277edc39d744146 https://doi.org/10.1016/s1359-6349(04)80049-1 Zobrazit plný text záznamu Full Text from ScienceDirect